CONMED Must Prove Organic Growth Can Reaccelerate Without Tariff Refund Help

CONMED raised its full-year earnings outlook last quarter, yet the stock has lagged the market ever since. That disconnect captures the tension heading into the third-quarter report, due after the close on October 28. The raise was real, but much of it came from a one-time tariff refund, a smaller-than-feared drag from the exited GI business, currency and buybacks. Meanwhile, the core business showed signs of slowing. This quarter is the first clean look at whether the underlying franchise can carry the guidance on its own.

The Street expects earnings of $1.00 per share on revenue of about $336.8 million. That implies a 7.4% decline in profit from the year-ago $1.08 and essentially flat sales. The headline revenue figure understates what management has promised, though. The GI exit is shrinking the reported top line, and the company guided to third-quarter organic growth of 6.4% to 7.6% excluding GI. That would be a sequential improvement from the second quarter. The earnings decline largely reflects interest expense, which is now expected to run about $33 million for the year versus $25 million to $27 million previously after the company replaced convertible debt with pricier bank borrowings. Management has flagged that cost as a headwind lasting into 2027.

For the full year, management now targets $4.48 to $4.60 per share on revenue of $1.358 billion to $1.373 billion. The consensus of $4.38 sits below the bottom of that range. That suggests analysts either have not fully absorbed the tariff refund or are skeptical that the second half will deliver. Revenue consensus of roughly $1.36 billion sits near the low end of guidance. Either way, the bar for the quarter looks modest relative to what the company has said it can do, which gives CONMED some room to clear expectations even if growth is merely on plan.

The operating questions are more interesting than the EPS line. AirSeal, the insufflation platform that management has positioned as a key growth driver, came in below expectations last quarter. That prompted a softer long-term growth framing of high single to low double digits. The expanded compatibility with Intuitive's DV5 system is already in guidance, so evidence that disposables and capital are accelerating would go a long way toward restoring confidence. US orthopedics is the other test. It was roughly flat in the second quarter during a commercial reorganization, after mid-single-digit gains in three of the prior four quarters. A return toward that pace would suggest the pause was temporary. Another flat print would raise harder questions about execution. BioBrace adoption, gross margin tracking toward the 57.5% to 58% range, and progress on bloated inventory are also worth watching. Inventory pushed the free cash flow target down to about $115 million from $125 million.

Sentiment has turned from modestly bearish before the last report to slightly bullish now. The stock trades at $46.05, comfortably above its 200-day average of $41.19 but nearer the bottom of its post-earnings range of $43.97 to $53.66. The previous quarter saw a sharp run from the low $30s, so some of the recovery story was already priced in before the market cooled on the quality of the beat.

Ultimately, this report hinges on organic growth landing inside, or ideally above, that 6.4% to 7.6% window, with AirSeal and US orthopedics doing the heavy lifting. If CONMED delivers that while reaffirming its full-year range, the earlier raise starts to look durable rather than engineered. A miss on organic growth would confirm the more cautious reading of last quarter and leave the elevated guidance resting on one-time help.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.